Iambic Therapeutics, Inc. SEC filings IAM

Iambic Therapeutics, Inc. has 46 filings in SEC EDGAR's recent list, going back to Oct 12, 2023. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.

Iambic Therapeutics, Inc. SEC filings
Form Description Filed Period
8-K Current report
Bylaw or fiscal year change, Regulation FD disclosure
Oct 16, 2026 Oct 16, 2026
424B4 Prospectus Oct 15, 2026 —
S-8 Employee stock plan registration Oct 15, 2026 —
EFFECT Filing Oct 14, 2026 —
CERT Filing Oct 14, 2026 —
8-A12B Filing Oct 13, 2026 —
S-1/A Amended registration statement Oct 8, 2026 —
S-1 Registration statement Sep 21, 2026 —
D Filing Sep 9, 2026 —
DRS/A Filing Aug 28, 2026 —
DRS Filing Jul 24, 2026 —
D Filing Apr 8, 2026 —
D Filing Nov 21, 2025 —
D/A Filing Jun 6, 2024 —
D/A Filing May 7, 2024 —
D Filing Apr 25, 2024 —
D Filing Oct 12, 2023 —

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IAM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC CIK
1997038

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.